Administration of Chlorpromazine as a Treatment for COVID-19
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04354805|
Recruitment Status : Unknown
Verified July 2020 by Ahmed Rezk, Cairo University.
Recruitment status was: Not yet recruiting
First Posted : April 21, 2020
Last Update Posted : July 8, 2020
|Condition or disease||Intervention/treatment||Phase|
|COVID-19||Drug: Chlorpromazine||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Single centred, single-blinded randomised controlled trial. All subjects from a population of interest will be randomly assigned to one of two groups, one group who is exposed to the intervention or a second group who receive the routine care in the hospital.|
|Official Title:||Administration of Chlorpromazine as a Treatment for COVID-19|
|Estimated Study Start Date :||August 1, 2020|
|Estimated Primary Completion Date :||October 2020|
|Estimated Study Completion Date :||November 2020|
Experimental: Group A
The group of 50 patients are going to receive Chlorpromazine (oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days) every 24 hours for 14 days in addition to the convential treatment of COVID-19 according to the Egyptian Ministry of Health protocol.
(Oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days)
Other Name: Neurazine, Largactil
No Intervention: Group B
A group of 50 patients control group who will recieve only the convential treatment of COVID-19 according to the Egyptian Ministry of Health protocol.
- Clinical improvement [ Time Frame: 2 weeks ]
In the current study, the clinical improvement will be determined by:
- Heart rate (pulse)
- Respiratory rate
- Oxygen saturation
- Need for oxygen
- Hospital stay time.
- CT lung involvement at day 0 and day 14.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04354805
|Contact: Ahmed Nasreldin Rezk||1118080934 ext firstname.lastname@example.org|
|Contact: Noha Nasreldin Hassan||1099433863 ext email@example.com|
|Cairo, Egypt, 11562|
|Contact: Ahmed Rezk 1118080934 ext 0020 firstname.lastname@example.org|
|Principal Investigator:||Ahmed Rezk||Cairo University|